ReviewProgress in molecular and subcellular biology2026
Biotechnological Applications of Bacteria.
Review in Progress in molecular and subcellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial biotechnology has historically relied heavily on bacteria, both in fundamental science and applied research. Their rapid growth capacity, ease of genetic manipulation, and extraordinary metabolic diversity enable them to offer a wide range of applications across all areas of modern biotechnology. Today, model bacteria such as Escherichia coli, Bacillus subtilis, and Pseudomonas species are at the center of multidimensional research ranging from recombinant protein production to biofuel synthesis, bioremediation, and probiotic therapies. The biotechnological potential of bacteria extends beyond industrial product development to enable the creation of sustainable solutions for global health, food safety, and environmental issues. In the medical field, bacteria serve as cellular factories for the large-scale production of recombinant proteins, including insulin, growth hormones, and monoclonal antibodies. Additionally, bacterial vectors are utilized as platforms in vaccine development and gene therapy applications. Probiotic bacteria are used to regulate the gut microbiota, strengthen the immune system, and prevent infections. In the agricultural sector, bacteria are utilized as biofertilizers, nitrogen-fixing agents (Rhizobium, Azotobacter), and biocontrol agents. They also contribute to reducing chemical fertilizer use by increasing productivity through the production of phytohormones that promote plant growth and by enhancing the availability of nutrients to plants. Bacteria have gained an important place in industrial applications by being used in the production of valuable metabolites such as antibiotics, vitamins, amino acids, and organic acids. With advances in metabolic engineering and synthetic biology, they are also involved in the production of biofuels, biodegradable plastics, and enzymes used in the food and textile industries. In environmental biotechnology, bacteria have a wide range of applications in bioremediation processes. Natural or genetically modified bacteria make important contributions to the degradation or detoxification of petroleum derivatives, heavy metals, and industrial waste. They also play critical roles in wastewater treatment and sustainable environmental management. In conclusion, bacteria serve as biological tools that offer innovative solutions in various areas of biotechnology. Advances in genomics, CRISPR-based gene editing, and systems biology are expanding the biotechnological applications of bacteria, increasing their importance by offering sustainable solutions to global issues such as health, food safety, and environmental protection.
Indexed as
Identifiers
41882396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.